Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians

Prev Med. 2011 Jan;52(1):10-5. doi: 10.1016/j.ypmed.2010.09.016. Epub 2010 Oct 8.


Objective: To examine US physicians' self-reported knowledge about the Polypill, factors considered in deciding whether to prescribe it, and acceptance of prescribing it for cardiovascular disease (CVD) prevention.

Methods: Numerical scales of 0 (lowest) to 5 (highest) were used to assess self-reported knowledge and importance of factors relevant to making a decision to prescribe a Polypill. Characteristics of physicians indicating they would prescribe a Polypill were compared.

Results: Among 952 physicians surveyed February through March 2010, mean self-rated knowledge about the Polypill was 2.0±1.5. Importance of degree of CVD event reduction, cost, and side effects were rated with means of 4.4, 4.3, and 4.3, respectively. 83% of respondents indicated they would "definitely" or "probably" prescribe it for high-risk patients; 62% would do so for moderate risk patients. Physicians with self-rated knowledge at ≥75th percentile were more likely to indicate they would prescribe a Polypill for moderate risk (adjusted OR 2.16; 95% CI 1.60-2.93) and high-risk (adjusted OR 1.57; 95% CI 1.07-2.32) patients.

Conclusion: Among this sample of physicians, there is relatively high acceptance of prescribing a Polypill for CVD prevention despite relatively modest knowledge about it.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antihypertensive Agents / administration & dosage*
  • Aspirin / administration & dosage*
  • Cardiovascular Diseases / prevention & control*
  • Drug Combinations
  • Female
  • Folic Acid / administration & dosage
  • Health Care Surveys
  • Health Knowledge, Attitudes, Practice
  • Hematinics / administration & dosage
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Male
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Practice Patterns, Physicians'*
  • Primary Prevention / methods
  • United States


  • Antihypertensive Agents
  • Drug Combinations
  • Hematinics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Folic Acid
  • Aspirin